Feed - Buzzberg

08:00
Jul 23 ◎

WST FY2026 Q2 Watch

West Pharmaceutical Services, Inc. (WST) FY2026 Q2 Earnings Call

WST NVO LLY ▾

Bob McMahon

Management raised full-year guidance significantly, citing broad-based strength in HVP components, GLP-1s, and biologics, with operating margin expansion exceeding 200 bps.

"We are increasing our full-year revenue and EPS guidance based on our good Q2 results and underlying momentum in the market."

WST WATCH

Eric Green

Asia Pacific grew 27% organically, driven by generic GLP-1 launches in China and India, plus increasing CDMO work in South Korea. — Generic GLP-1 entrants in emerging markets are adopting West's high-value components, expanding total addressable market beyond branded GLP-1s.

"Asia Pacific led the way with 27% organic growth as we look to capitalize on the significant market expansion and innovation in that region."

NVO WATCH LLY WATCH

HIGH

08:00
Apr 23 ◎

WST FY2026 Q1 Watch

West Pharmaceutical Services, Inc. (WST) FY2026 Q1 Earnings Call

08:00
Feb 12 ◎

WST FY2025 Q4 Watch

West Pharmaceutical Services, Inc. (WST) FY2025 Q4 Earnings Call

LLY NVO WST ▾

Eric Green

Management cites Eli Lilly and Novo Nordisk's public commentary that oral GLP-1s are expanding the market rather than cannibalizing injectables, supporting continued demand for West's injectable components.

"I'd encourage you to listen to publicly available remarks from the two leading companies at producing GLP-1s and their expectation that orals will expand and not substitute injectables in the marketplace. Both companies have noted that"

LLY WATCH

Eric Green

Management endorses Novo Nordisk's view that orals are additive, not substitutive, reinforcing West's GLP-1 growth thesis.

NVO WATCH

Bob McMahon

Management guides FY2026 revenue and EPS growth, citing momentum from HVP components and margin expansion, while embedding conservative GLP-1 assumptions.

"For the year, we anticipate revenue to be in the range of $3.215 billion to $3.275 billion. Reported growth is 4.6% to 6.5%, and with FX and the smart dose adjustment roughly offsetting to get to our organic growth range of 5% to 7% for"

WST WATCH

HIGH

08:00
Oct 23 ◎

WST FY2025 Q3 Watch

West Pharmaceutical Services, Inc. (WST) FY2025 Q3 Earnings Call

WST LLY NVO ▾

Eric Green

Management raised full-year guidance, citing re-accelerating demand in HVP components, strong GLP-1 and Annex 1 tailwinds, and improving market conditions. The tone is confident about a sustainable recovery and margin expansion into 2026.

"business momentum is steadily improving, and we expect this trend to continue."

WST WATCH

Eric Green

GLP-1 elastomers now 9% of total sales (vs mid-single-digits in 2024) and growing faster than end-market script data, driven by vial usage, generics, and clinical-trial demand. — West is benefiting disproportionately as GLP‑1 drugmakers expand vial presentations and pipeline molecules, implying higher-than-expected component demand for Lilly and Novo Nordisk.

"GLP‑1 elastomers had strong growth and now account for 9% of total company sales."

LLY WATCH NVO WATCH

HIGH

Feed — Buzzberg